pharma · Schizophrenia · Alzheimer's Disease Psychosis · ACAD
Acadia Pharmaceuticals B.V.
Acadia Pharmaceuticals is a pharma organization headquartered in Indianapolis, USA. It trades on NYSE under ticker ACAD. Primary therapeutic focus areas include Schizophrenia, Alzheimer's Disease Psychosis, Parkinson Dis
Phase 2 · small molecule · Parkinson Disease
Pimavanserin 17mg is a small-molecule oral therapeutic developed by Acadia Pharmaceuticals B.V. for Parkinson Disease, currently in Phase 2 development. The program (internal code 6398) is based on pimavanserin tartrate, the active pharmaceutical ingredient in NUPLAZID, which has already achieved FDA approval for psych
Internal code 6398
Pimavanserin 17mg is a small-molecule oral therapeutic developed by Acadia Pharmaceuticals B.V. for Parkinson Disease, currently in Phase 2 development. The program (internal code 6398) is based on pimavanserin tartrate, the active pharmaceutical ingredient in NUPLAZID, which has already achieved FDA approval for psychosis associated with Parkinson Disease. The Phase 2 program represents a potential label expansion or formulation optimization strategy, with the latest milestone recorded on 16 March 2026. Pimavanserin is a selective serotonin 5-HT2A receptor inverse agonist that addresses neuropsychiatric complications in Parkinson patients. The regulatory pathway benefits from the established safety and efficacy profile of the parent molecule, which is marketed under multiple approvals including the original NDA207318 and subsequent ANDAs. Acadia's strategy appears focused on advancing treatment options within the Parkinson Disease space, where neuropsychiatric symptoms represent a significant unmet medical need. The Phase 2 completion status indicates the program has transitioned beyond early-stage development, positioning it for potential advancement toward pivotal trials or regulatory submission.
Parkinson Disease affects millions globally and is characterized not only by motor symptoms but also by neuropsychiatric complications including psychosis, depression, and cognitive decline. These neuropsychiatric manifestations significantly impair quality of life and caregiver burden, yet treatment options remain limited. Pimavanserin addresses this unmet need by targeting hallucinations and delusions specifically associated with Parkinson Disease psychosis, a condition that affects 20–40% of Parkinson patients. The approved NUPLAZID formulation has demonstrated clinical utility, but the Phase 2 program for the 17mg strength suggests Acadia is exploring optimized dosing, formulation, or expanded indications to enhance therapeutic outcomes or patient convenience. The competitive landscape includes multiple Phase 3 programs (Dipraglurant, CEP-1347, Rivastigmine Transdermal, BIIB122, Pramipexol ER) and approved agents (ROP, CREXONT ER), indicating robust market interest. However, pimavanserin's established regulatory precedent and mechanism differentiation provide competitive advantage. The Parkinson Disease market is expanding due to aging populations and improved diagnostic awareness, making label expansions and optimized formulations commercially significant. Success in this Phase 2 program could support market share consolidation and premium pricing within the neuropsychiatric Parkinson segment.
Drug Class: Selective serotonin 5-HT2A receptor inverse agonist (atypical antipsychotic mechanism without dopamine antagonism).
Modality: Small-molecule oral therapeutic.
Route of Administration: Oral.
Active Ingredient: Pimavanserin tartrate.
Brand Name: NUPLAZID (approved formulations).
Formulation Strategy: The Phase 2 program evaluates a 17mg strength tablet, suggesting dose optimization or alternative formulation relative to approved NUPLAZID products.
Related Therapies: Approved comparators include ROP (GlaxoSmithKline) and CREXONT ER (Amneal Pharma Europe Ltd). Competitive Phase 3 agents include Dipraglurant (Addex Therapeutics), CEP-1347 (Teva), Rivastigmine Transdermal (United Therapeutics), BIIB122 (Denali), and Pramipexol ER (Boehringer Ingelheim).
First Approval: NUPLAZID (pimavanserin tartrate) approved by FDA under NDA207318 for psychosis associated with Parkinson Disease; subsequent generic/ANDA approvals issued to Zydus and MSN (ANDA214493, ANDA214502, ANDA214925).
Patent Status: Not yet disclosed in available facts.
Also known as: PD, Parkinson's disease, paralysis agitans
Prevalence: Parkinson disease affects approximately 1-2 million individuals in North America and Europe, with an estimated global prevalence of 6-7 million people. Incidence rates range from 8-18 cases per 100,000 person-years, with prevalence increasing substantially with age, particularly in populations over 60 years. The disease accounts for significant morbidity and healthcare burden, with prevalence expected to increase as populations age.
Parkinson disease is a progressive neurodegenerative disorder characterized by the loss of dopamine-producing neurons in the substantia nigra region of the brain. The condition manifests with motor symptoms including bradykinesia (slowness of movement), resting tremor, rigidity, and postural instability, as well as non-motor symptoms such as cognitive decline, depression, sleep disturbances, and autonomic dysfunction. Parkinson disease typically affects adults aged 60 years and older, though early-onset forms can occur in younger individuals. The disease progresses over years to decades, with significant variability in symptom presentation and disease trajectory among patients.
ClinicalTrials.gov lists 13 registered studies for PD - Parkinson's Disease (AACT aggregate).
Phase breakdown: NA (11), PHASE1 (1), PHASE4 (1)
Common investigational therapies:
Current standard of care emphasizes individualized, symptom-based management tailored to disease stage and patient characteristics. Early-stage disease typically begins with dopamine agonists or MAO-B inhibitors in younger patients to delay levodopa initiation, while older patients or those with significant motor symptoms often receive levodopa-based therapy. As disease progresses, combination therapy becomes common, with optimization of dosing intervals and addition of adjunctive agents to manage motor complications such as dyskinesias and motor fluctuations. Non-motor symptoms receive targeted treatment with appropriate pharmacotherapy. Deep brain stimulation is considered for advanced disease with motor complications inadequately controlled by medication. Multidisciplinary care involving neurology, physical therapy, occupational therapy, and speech-language pathology is recommended to optimize outcomes and quality of life.
Significant unmet medical needs persist in Parkinson disease management. Disease-modifying therapies that halt or reverse neurodegeneration remain unavailable, with current treatments providing only symptomatic relief. Early biomarker identification and disease-modifying interventions for presymptomatic or early-stage disease represent critical gaps. Better management of motor complications, including dyskinesias and motor fluctuations, is needed as patients develop tolerance to levodopa. Non-motor symptoms including cognitive decline, dementia, autonomic dysfunction, and psychiatric manifestations remain inadequately addressed by current therapies. Long-acting formulations with improved tolerability and reduced dosing frequency would enhance patient adherence and quality of life. Therapies targeting disease heterogeneity and genetic subtypes, particularly for monogenic forms, require further development. Additionally, improved understanding of disease mechanisms and development of neuroprotective agents with proven efficacy represent major therapeutic opportunities.
Disease data sourced from MONDO Disease Ontology (MONDO:0005180), Orphanet — Parkinson disease, NCT03330353, NCT05376761, NCT05550714, NCT05895019, NCT06482268, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
Phase 2 enrollment and conduct
Phase 2 trial NCT03947216 conducted to evaluate pimavanserin 17mg in Parkinson Disease.
Latest milestone recorded
Most recent program activity or milestone status update as of 16 March 2026; specific milestone detail not yet disclosed.
The Parkinson Disease neuropsychiatric treatment landscape is increasingly competitive. Pimavanserin (Acadia) holds first-mover advantage with FDA-approved NUPLAZID, establishing clinical precedent and market presence. GlaxoSmithKline's ROP and Amneal's CREXONT ER represent approved alternatives. Multiple Phase 3 programs are advancing: Addex's Dipraglurant, Teva's CEP-1347, United Therapeutics' Rivastigmine Transdermal, Denali's BIIB122, and Boehringer Ingelheim's Pramipexol ER. Phase 2 competitors include Vistagen's AV-101 and Takeda's TAK-071. Pimavanserin's differentiation rests on its selective 5-HT2A inverse agonism without dopamine antagonism, reducing motor side effects compared to traditional antipsychotics. The Phase 2 program for the 17mg strength suggests Acadia is optimizing dosing or formulation to enhance efficacy, tolerability, or patient compliance. The competitive intensity indicates strong market demand but also rising barriers to differentiation. Success will depend on demonstrating superior efficacy, safety, or convenience relative to approved and pipeline competitors.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| Pimavanserin | Acadia Pharmaceuticals B.V. | small_molecule | approved |
| ROP | GlaxoSmithKline | small_molecule | approved |
| CREXONT ER | Amneal Pharma Europe Ltd | small_molecule | approved |
| Dipraglurant | Addex Therapeutics | small_molecule | phase_3 |
| CEP-1347 10mg | Teva Pharma GmbH | small_molecule | phase_3 |
| Rivastigmine Transdermal System | United Therapeutics Europe Ltd | small_molecule | phase_3 |
| BIIB122 | Denali Therapeutics | small_molecule | phase_3 |
| Pramipexol Extended Release | Boehringer Ingelheim | small_molecule | phase_3 |
| [123I]β-CIT | United Therapeutics Europe Ltd | small_molecule | phase_2 |
| levodopa | United Therapeutics Europe Ltd | small_molecule | phase_2 |
| AV-101 | Vistagen Therapeutics | small_molecule | phase_2 |
| TAK-071 | Takeda | small_molecule | phase_2 |
| TRIHEXYPHENIDYL | — | Muscarinic acetylcholine receptor M1 antagonist | Approved |
| TOLCAPONE | — | Catechol O-methyltransferase inhibitor | Approved |
| SELEGILINE | — | Monoamine oxidase B inhibitor | Approved |
| SAFINAMIDE MESYLATE | — | Monoamine oxidase B inhibitor | Approved |
| SAFINAMIDE | — | Monoamine oxidase B inhibitor | Approved |
| ROTIGOTINE | — | D2-like dopamine receptor agonist | Approved |
| ROPINIROLE HYDROCHLORIDE | — | D2-like dopamine receptor agonist | Approved |
| ROPINIROLE | — | D2-like dopamine receptor agonist | Approved |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
United States (FDA): Pimavanserin tartrate (NUPLAZID) approved under NDA207318 for psychosis associated with Parkinson Disease. Generic/ANDA approvals issued: ANDA214493 (Zydus), ANDA214502 (MSN), ANDA214925 (Zydus). Additional NDA210793 recorded. The Phase 2 program for the 17mg strength is a subsequent development, likely representing a label expansion, dose optimization, or formulation variant.
European Medicines Agency (EMA): Regulatory status not yet disclosed in available facts.
PMDA (Japan): Regulatory status not yet disclosed in available facts.
NMPA (China): Regulatory status not yet disclosed in available facts.
Regulatory Strategy: Acadia's Phase 2 program appears designed to support potential label expansion, new indication, or optimized formulation within the Parkinson Disease space, leveraging the established safety and efficacy profile of approved NUPLAZID.
Pimavanserin 17mg is being developed for Parkinson Disease, specifically to address neuropsychiatric symptoms such as psychosis, hallucinations, and delusions associated with the condition.
Yes, pimavanserin tartrate (NUPLAZID) is FDA-approved for psychosis associated with Parkinson Disease under NDA207318. The Phase 2 program for the 17mg strength represents a subsequent development, potentially for label expansion or formulation optimization.
Pimavanserin is a selective serotonin 5-HT2A receptor inverse agonist that reduces neuropsychiatric symptoms in Parkinson Disease without blocking dopamine receptors, thereby avoiding motor side effects associated with traditional antipsychotics.
Pimavanserin is developed and marketed by Acadia Pharmaceuticals B.V. (and Acadia Pharms Inc). Generic versions are manufactured by Zydus and MSN under ANDA approvals.
The Phase 2 program for pimavanserin 17mg is completed as of March 2026. The next development stage and regulatory pathway have not yet been disclosed.
The Phase 2 program is supported by trial NCT03947216. Detailed trial design, participant demographics, endpoints, and results have not yet been disclosed.
Approved competitors include ROP (GlaxoSmithKline) and CREXONT ER (Amneal). Phase 3 competitors include Dipraglurant (Addex), CEP-1347 (Teva), Rivastigmine Transdermal (United Therapeutics), BIIB122 (Denali), and Pramipexol ER (Boehringer Ingelheim).
Pimavanserin is a selective 5-HT2A receptor inverse agonist, a mechanism distinct from dopamine antagonism, making it suitable for treating psychosis in Parkinson patients without worsening motor symptoms.
Pimavanserin 17mg is administered orally as a tablet formulation.
Yes, generic versions of pimavanserin tartrate have been approved by the FDA under ANDA applications by Zydus (ANDA214493, ANDA214925) and MSN (ANDA214502).
Pimavanserin addresses neuropsychiatric complications of Parkinson Disease, including hallucinations, delusions, and psychosis, which affect 20–40% of Parkinson patients and significantly impair quality of life.
No partner or licensee is disclosed for the Phase 2 program; development is being conducted by Acadia Pharmaceuticals B.V.
Peak sales projections have not yet been disclosed for the Phase 2 program.
The expected next milestone label and date have not yet been disclosed; monitoring for Phase 2 data readout and regulatory guidance will be important.
The internal program code is 6398.
NUPLAZID is approved by the FDA under NDA207318 and NDA210793 for psychosis associated with Parkinson Disease. EMA, PMDA, and NMPA regulatory status have not yet been disclosed.
Active drug: pimavanserin 17mg (2 strength tablets) → Drug → Target → Indication → Company → Trials → Competitors
Strategic Implications: Acadia's Phase 2 program for pimavanserin 17mg represents a focused development strategy within the Parkinson Disease neuropsychiatric segment. The completion of Phase 2 as of March 2026 suggests the program is advancing toward potential Phase 3 initiation or regulatory submission, contingent on positive efficacy and safety data. The 17mg strength formulation may address dosing optimization, improved tolerability, or enhanced patient convenience compared to approved NUPLAZID products.
Competitive Implications: Pimavanserin maintains first-mover advantage in the FDA-approved Parkinson psychosis market, but intensifying Phase 3 competition from Dipraglurant, CEP-1347, and others necessitates differentiation. Success of the Phase 2 program could support label expansion or market consolidation. Failure or delays would strengthen competing agents' market positioning.
Future Catalysts: Expected milestones include Phase 2 data readout (timing not yet disclosed), potential Phase 3 initiation, regulatory interactions with FDA regarding indication or formulation strategy, and competitive trial readouts from Phase 3 programs. Peak sales projections and consensus analyst positioning not yet disclosed.
Expected Milestones: Next milestone label and date not yet disclosed; monitoring Phase 2 data presentation and regulatory guidance will be critical to assess program trajectory.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.